Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This is an open, prospective, single-arm, multi-cohort clinical study to evaluate the
efficacy and safety of surufatinib alone or combined with Anti-PD-1 mAb in the treatment of
advanced Hepatocellular Carcinoma